Learn more about delivery challenges from the oncology pipeline in this podcast! With each mode of therapeutic delivery comes differences in their efficacy, complexity, and stakeholders impacts. Hear how leaders from Amgen, Catalent Pharma Solutions, Johnson & Johnson, and Astellas Pharma approach this issue and strike a balance between these priorities. Listen to podcast here: https://lnkd.in/enFxZ2pf #ImmunoOncology #IO360 #Oncology
Immuno-Oncology 360° Community News’ Post
More Relevant Posts
-
📅 Add this to your 2024 calendar! 📅 Returning to Boston in July, the 4th Induced Proximity-Based Drug Discovery Summit will unite 100+ small molecule and biologics experts in the race to develop new stabilization, modulation, post-translational modification and inactivation/activation modalities for novel target spaces. So, if your excited about DUBTACs, curious about PHICS, caught up on AUTOTACs or invested in the development of molecular glues or induced proximity biologics don't miss out on hearing the latest developments and innovations from Apertor Pharmaceuticals, TRIANA Biomedicines, Magnet Biomedicine, Photys Therapeutics, PAQ Therapeutics, Rapafusyn Pharmaceuticals, EpiBiologics, Gandeeva Therapeutics, Vicinitas Therapeutics, Novartis, Genentech, Dana-Farber Cancer Institute, Lyterian Therapeutics, Broad Institute of MIT and Harvard, AstraZeneca, Solu Therapeutics, AUTOTAC BIO Inc., Kronos Bio, Goethe University Frankfurt, Nurix Therapeutics, and many more! To explore all expert-led talks, view the 2024 Agenda here: 👉 https://lnkd.in/ec3JYh_q 👈 #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC
To view or add a comment, sign in
-
-
📣 Calling all DUBTAC, CyTAC, EpiTAC, PHICS and Molecular Glue Fanatics 📣 The long established 4th Induced Proximity-Based Drug Discovery Summit is returning to Bostin this July 23-25, 2024, to explore the emerging proximity phenomenon!! Check out the official event guide here 👉https://lnkd.in/er2TX2Bu Taking on knowledge gaps in validating novel mechanisms of action, accessing diverse chemical matter, and rationally designing selective and potent small molecules and biologics for novel target spaces, hear first-hand from pioneering leaders at Vicinitas Therapeutics, Gandeeva Therapeutics, Apertor Pharmaceuticals, TRIANA Biomedicines, Magnet Biomedicine, Photys Therapeutics, Rapafusyn Pharmaceuticals, Dana-Farber Cancer Institute, AstraZeneca, Genentech, AUTOTAC BIO Inc., Goethe University Frankfurt, Nurix Therapeutics, Kronos Bio, Solu Therapeutics, Broad Institute of MIT and Harvard, Lyterian Therapeutics, PAQ Therapeutics, EpiBiologics, Novartis and many more! To explore all expert-led talks, view the 2024 Agenda here👉https://lnkd.in/eNmryrhm 👈 #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC
To view or add a comment, sign in
-
-
Another great example of how Mass Spectrometry Imaging (#MSI, IMSIS Conference) can support new drug development by providing spatial pharmacokinetics data about compound biodistribution in complex disease models as #glioblastoma. MSI was used to demonstrate the ability of a compound to penetrate CNS in both naïve and tumour-bearing brains and assess its preferential accumulation within the glioma region as shown in the picture below. Special thanks to Anna Staniszewska and Petra Hamerlik as well as all the team for this great cross-department collaborative work. Link to the paper: https://lnkd.in/esiuRswP #WhatScienceCanDo #spatialbiology #pharmaceuticals #massspectrometry #molecularimaging #drugdiscovery #cancerresearch #clinicalresearch #oncology
To view or add a comment, sign in
-
-
💊 🔬 Join KCAS Bio for an enlightening webinar as we explore the expanding role of hybrid LC-MS/MS in ADC analysis. Discover how this innovative approach offers flexibility and multiple advantages, allowing for the simultaneous monitoring of total antibodies and ADCs, irrespective of conjugation type or linker used. From oncology to novel modalities like antibody-peptide conjugates and antibody-RNA conjugates (ARCs), hybrid LC-MS/MS is reshaping the landscape of drug development. Don't miss this opportunity to gain insights from Dawn Dufield into the transformative potential of hybrid LC-MS/MS and enhance your bioanalytical capabilities. ➡️ REGISTER HERE: https://buff.ly/4aMa6wF #DrugDevelopment #Biosimilars #Bioanalytical #MassSpectrometry #LaboratoryTechnology #LiquidChromatography #BioanalyticalTesting
To view or add a comment, sign in
-
-
Save big and gain access to learnings even bigger, with savings of up to $1,100 on your pass for the 4th Induced Proximity-Based Drug Discovery Summit. Secure your seat amongst 80+ heterobifunctional, monovalent and biologics experts to hear the latest insights on: 🔴 Efficiently identifying & validating novel DUB Recruiters & DUBTACs with insights from Tyzoon Nomanbhoy, Vicinitas Therapeutics 🔴Developing induced proximity drugs with ADCs to demonstrate improved potency and selectivity with insights from Thomas Pillow, Genentech 🔴Leveraging CyTACs (Cytotoxicity Targeting Chimeras) to unlock GPCRs & Ion Channels with insights from Brandon Turunen, Solu Therapeutics 🔴Targeting mutant KRAS though precision modulation of protein phosphorylation with PHICS technology with insights from Moses Moustakim, Photys Therapeutics Not to mention experts from Kronos Bio, Rapafusyn Pharmaceuticals, Novartis Institute For Biomedical Research, Magnet Biomedicine, Dana-Farber Cancer Institute, EpiBiologics, Gandeeva Therapeutics and many more will all be sharing BRAND-NEW DATA! Check out the full event guide here: https://ter.li/4m8eg2 📣 Head to the online registration page to secure the early bird discount today or feel free to connect with me for more information! 📣 #InducedProximity #DUBTAC #PHIC #EpiTac #LYTAC #CyTAC #AceTAC #PHOSTAC #RiboTAC #MolecularGlue #TPD #TAC
To view or add a comment, sign in
-
-
Double your Impact this #GivingTuesday!✨ Your gift before midnight TONIGHT will be MATCHED up to $20,000 thanks to a generous supporter of the LRA! 💜 🟣 $50 ➔ $100 🟣 $100 ➔ $200 🟣 $250 ➔ $500 Your contribution funds the hardworking scientists and researchers who are working tirelessly to discover new treatments and ultimately a cure for lupus. This past year alone, the LRA has awarded millions in new research grants. And our clinical affiliate Lupus Therapeutics is collaborating with several biopharmaceutical companies to support clinical studies and development programs - including exciting cell therapies like CAR-T that build on pioneering LRA-funded work and hold the potential to shift the lupus treatment paradigm. Together, we will fund the most promising projects, find new and personalized treatments, and one day discover a cure. Give today to make a lasting impact. 🎁 https://bit.ly/LRAGIVE23 #lupus #LupusResearch #GiveToday
To view or add a comment, sign in
-
Exciting Announcement! Join us for a webinar hosted by Vellon Space on Exploring the opportunities and Utilizing Space for Scientific Research | 23rd May, 6-7PM. Registration Link : https://lu.ma/s3pwtnc4 🔬 Are you ready to unlock the mysteries of space for scientific research? Join us for an illuminating webinar where we'll explore the boundless opportunities that space offers for industries ranging from biotechnology to material science. 🛰️ Vellon Space is proud to present a webinar featuring expert speakers who will delve into topics crucial for scientific advancement: 1️⃣ Material Science & In-Space Manufacturing: Learn how microgravity environments can revolutionize material science and manufacturing processes, opening new doors for innovation. 2️⃣ Drug Testing and Discovery in Space: Discover the unique advantages space provides for drug testing and the potential breakthroughs it offers for pharmaceutical research. 3️⃣ Cancer Studies on Organoids: Explore the frontier of cancer research as we discuss the promising developments in studying cancer using organoids in space. 📅 Save the Date: May 23rd, 6-7pm IST #space #biotech #pharma #lifescience #microgravity #deeptech #material #semiconductor
To view or add a comment, sign in
-
-
Join us for an exciting deep dive into the specifics of organoid-based drug screening with our detailed webinar! 👏 👏 Dr. Marrit Putker, a leading expert in organoid technology, will guide us through the entire organoid screening process, from conception to application. Discover how these groundbreaking advancements are revolutionizing the prediction of drug efficacy and response, bridging the gap between the lab and clinical outcomes. Don't miss this opportunity to learn from the best and stay at the forefront of medical innovation!
🔴Live Today - 10am and 3pm ET! Join our webinar on the future of drug discovery with Dr. Marrit Putker, an expert in organoid technology➡️https://hubs.la/Q02yYY8v0 You Will Learn: ➡️Large-Scale Organoid Panel Drug Screening: Explore the revolutionary OrganoidXplore™ for high-throughput screening and its pivotal role in enhancing clinical outcomes. ➡️Reproducibility & Predictive Accuracy: Unveil the high correlation between in vitro and in vivo results. ➡️Efficiency & Clinical Applications: Learn how this technology aids in early patient stratification in clinical trials. #Organoids #DrugDiscovery
Webinar: Large-Scale Organoid Panel Screening: Revolutionizing Oncology Drug Discovery
crownbio.com
To view or add a comment, sign in
-
Our Head of Translational Medicine Kenneth Crook will be presenting Engimmune's AI-guided platform technologies for soluble TCR drug development at Immuno 2024 on April 25-26. In this video, we get his perspective on current trends in immuno-oncology and on how specTR molecules (specificity- and affinity-enhanced soluble TCR engagers) can address key challenges in the treatment of solid tumours. https://lnkd.in/eP7XteCS
Dive into the future of immuno-oncology with Kenneth Crook, Head of Translational Medicine at Engimmune Therapeutics. Gain exclusive insights into his upcoming presentation at Immuno 2024 and discover what's on the horizon for this dynamic field! 🧬 Meet Kenneth and be part of the conversation: https://hubs.la/Q02rsR310 #OGImmuno #Immuno24
To view or add a comment, sign in
-
Missed out on this year's #ASMS conference? That doesn’t mean you have to miss out on the exciting science we shared! Check out this poster presented by Jeremiah Bowers, based on a collaboration with MOMA Therapeutics. By leveraging cutting-edge proteomic technologies and mass spectrometry workflows developed by Momentum, Bowers and colleagues were able to identify and characterize several covalent cysteine modifiers active against cancer-driving helicases. Their research demonstrates the power of mass spec covalent binding screening, modification mapping, and occupancy calculations in taking a project from screening to hit characterization with unmatched efficiency. Want to learn more about this project? Request the full poster here: https://lnkd.in/e6GFCEvW #CancerResearch #DrugDiscovery #RapidFireMS, #OrbitrapAscend #Covalent #Chemoproteomics #Chemicalbiology
To view or add a comment, sign in
-